Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China flag China · Delayed Price · Currency is CNY
27.59
+0.71 (2.64%)
Oct 30, 2026, 3:00 PM CST

SHA:600566 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
5,9106,2057,9979,6388,9767,618
Other Revenue
14.1114.1120.3816.5119.8713
5,9246,2198,0179,6558,9967,631
Revenue Growth
-3.58%-22.43%-16.96%7.32%17.90%23.77%
Cost of Revenue
1,1111,3091,6661,7841,5371,277
Gross Profit
4,8134,9096,3507,8717,4596,354
Selling, General & Admin
2,4062,5593,3874,3794,4774,031
Research & Development
433.4385.1444.78464.4553.3523.44
Other Operating Expenses
101.56105.98114.37146.24138.81120.9
Operating Expenses
2,9693,0553,9244,9875,2054,683
Operating Income
1,8441,8552,4272,8842,2541,671
Interest Expense
-2.04-11.45-27.27-17.58-30.41-34.9
Interest & Investment Income
247.64256.71352.77357.81183.21171.42
Currency Exchange Gain (Loss)
-0.01-0.01----
Other Non Operating Income (Expenses)
64.77-0.8-1.03-0.83-1.2-0.41
EBT Excluding Unusual Items
2,1542,0992,7513,2232,4051,807
Gain (Loss) on Sale of Investments
-48.341.3199.214.6-7.32114.55
Gain (Loss) on Sale of Assets
0.340.170.20.135.220.65
Asset Writedown
-9.79-0.45-0.28-1.09-0.53-0.42
Other Unusual Items
43.822.17127.9760.42105.0928.96
Pretax Income
2,1412,1622,9783,2972,5081,950
Income Tax Expense
340.89383.99441.54470.03336.2233.22
Earnings From Continuing Operations
1,8001,7782,5372,8272,1721,717
Minority Interest in Earnings
16.77-0.41-5.15-4.28-0.971.96
Net Income
1,8161,7782,5322,8232,1711,719
Net Income to Common
1,8161,7782,5322,8232,1711,719
Net Income Growth
10.01%-29.77%-10.32%30.04%26.27%34.60%
Shares Outstanding (Basic)
922921917916890886
Shares Outstanding (Diluted)
922921917916908900
Shares Change
0.40%0.43%0.08%0.91%0.91%7.82%
EPS (Basic)
1.971.932.763.082.441.94
EPS (Diluted)
1.971.932.763.082.391.91
EPS Growth
9.57%-30.07%-10.39%28.87%25.13%24.84%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,2251,1022,0023,1622,3771,646
Free Cash Flow Per Share
1.331.202.183.452.621.83
Dividend Per Share
1.7401.7402.0901.3000.8800.680
Dividend Growth
-16.75%-16.75%60.77%47.73%29.41%51.11%
Gross Margin
81.25%78.95%79.21%81.52%82.91%83.27%
Operating Margin
31.13%29.82%30.27%29.87%25.05%21.89%
Profit Margin
30.66%28.59%31.58%29.24%24.13%22.53%
Free Cash Flow Margin
20.68%17.73%24.97%32.76%26.42%21.57%
EBITDA
2,1382,1542,7333,1852,5611,964
EBITDA Margin
36.09%34.63%34.09%32.99%28.47%25.74%
D&A For EBITDA
293.5299.16306.7301.2307.14293.13
EBIT
1,8441,8552,4272,8842,2541,671
EBIT Margin
31.13%29.82%30.27%29.87%25.05%21.89%
Effective Tax Rate
15.93%17.76%14.83%14.26%13.41%11.96%
Revenue as Reported
2,2876,2198,0179,6558,9967,631